Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | PGR | P06401 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Laquinimod SCHEMBL29438575 | 1.00 | TP53 (0.50) | TP53MEN1KMT2APGREGFR | |
| Laquinimod SCHEMBL1573491 | 0.99 | TP53 (0.49) | TP53MEN1KMT2APGREGFR | |
| Laquinimod SCHEMBL1573704 | 0.99 | TP53 (0.49) | TP53MEN1KMT2APGREGFR | |
| Laquinimod SCHEMBL1573337 | 0.99 | TP53 (0.49) | TP53MEN1KMT2APGREGFR | |
| Laquinimod SCHEMBL1573702 | 0.99 | TP53 (0.49) | TP53MEN1KMT2APGREGFR | |
| Laquinimod SCHEMBL12009979 | 0.94 | TP53 (0.48) | TP53MEN1KMT2APGREGFR | |
| Laquinimod SCHEMBL4695786 | 0.93 | TP53 (0.44) | TP53MEN1KMT2APGREGFR | |
| SCHEMBL23531675 | 0.92 | HDAC4 (0.43) | TP53MEN1KMT2APGREGFR | |
| SCHEMBL7538318 | 0.92 | HDAC4 (0.43) | TP53MEN1KMT2APGREGFR | |
| SCHEMBL29972688 | 0.92 | HDAC4 (0.43) | TP53MEN1KMT2APGREGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 5268 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138973-A1 | SUBSTITUTED PYRIDINES FOR USE IN TREATING OR PREVENTING INFLAMMATORY DISEASES OR DISEASES ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE | SITRYX THERAPEUTICS LTD (GB) | 2026-05-21 | — | — | US | claimed |
| US-20260137680-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LTD (GB) | 2026-05-21 | — | — | US | claimed |
| US-12617762-B2 | Carboxy derivatives with antiinflamatory properties | SITRYX THERAPEUTICS LIMITED (GB) | 2026-05-05 | — | — | US | claimed |
| EP-4461364-B1 | LAQUINIMOD FORMULATION FOR OCULAR USE | ACTIVE BIOTECH AB (SE) | 2026-04-22 | — | — | EP | claimed |
| US-20260085061-A1 | PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS | SITRYX THERAPEUTICS LIMITED (GB) | 2026-03-26 | — | — | US | claimed |
| EP-4081511-B3 | CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES | SITRYX THERAPEUTICS LTD (GB) | 2026-03-04 | — | — | EP | claimed |
| EP-4701663-A1 | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS, COMBINATIONS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-03-04 | — | — | EP | claimed |
| US-12461098-B2 | Biomarkers for multiple sclerosis | GLX ANALYTIX APS (DK) | 2025-11-04 | — | — | US | claimed |
| EP-4640714-A2 | METHODS FOR ASSESSING RISK OF DEVELOPING A VIRAL DISEASE USING A GENETIC TEST | PML Screening, LLC (US) | 2025-10-29 | — | — | EP | claimed |
| EP-4634167-A1 | SUBSTITUTED PYRIDINES FOR USE IN TREATING OR PREVENTING INFLAMMATORY DISEASES OR DISEASES ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE | Sitryx Therapeutics Limited (GB) | 2025-10-22 | — | — | EP | claimed |
| US-6875869-B2 | Process for the manufacture of quinoline derivatives | ACTIVE BIOTECH AB (SE) | 2005-04-05 | — | — | US | claimed |
| US-20040034227-A1 | Process for the manufacture of quinoline derivatives | ACTIVE BIOTECH AB (SE) | 2004-02-19 | — | — | US | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| EP-1073639-B1 | QUINOLINE DERIVATIVES | ACTIVE BIOTECH AB (SE) | 2002-11-27 | — | — | EP | claimed |
| EP-1224172-A1 | DRUGS FOR THE TREATMENT OF MALIGNANT TUMOURS | Active Biotech AB (SE) | 2002-07-24 | — | — | EP | claimed |
| US-6395750-B1 | Includes laquinimod, N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxo-quinoline-3-carboxamide and its salts; breat or prostate cancer | ACTIVE BIOTECH AB (SE) | 2002-05-28 | — | — | US | claimed |
| WO-2001030758-A1 | DRUGS FOR THE TREATMENT OF MALIGNANT TUMOURS | ACTIVE BIOTECH AB (SE) | 2001-05-03 | — | — | WO | claimed |
| EP-1073639-A1 | QUINOLINE DERIVATIVES | Active Biotech AB (SE) | 2001-02-07 | — | — | EP | claimed |
| US-6077851-A | USED FOR TREATMENT OF DISEASES RESULTING FROM AUTOIMMUNITY SUCH AS MULTIPLE SCLEROSIS, INSULIN-DEPENDENT DIABETES MELLITUS, SYSTEMIC LUPUS ERYTHEMATOSUS, RHEUMATOID ARTHRITIS, INFAMMATORY BOWEL DISEASE AND PSORIASIS; LAQUINIMOD AS NEW CHEMICAL ENTITY | ACTIVE BIOTECH AB (SE) | 2000-06-20 | — | — | US | claimed |
| WO-1999055678-A1 | QUINOLINE DERIVATIVES | ACTIVE BIOTECH AB (SE) | 1999-11-04 | — | — | WO | claimed |